

Novel Therapeutic Approaches for the Treatment of Leishmaniasis

Vandana Soni¹, Silki Chandel¹, Vikas Pandey¹, Saket Asati¹,
Priyanka Jain¹, Aviral Jain² and Rakesh K. Tekade³

¹Department of Pharmaceutical Sciences, Dr. Hari Singh Gour University, Sagar, India

²Ravi Shankar College of Pharmacy, Bhopal, India ³National Institute of Pharmaceutical Education and Research (NIPER)—Ahmedabad, Gandhinagar, India

OUTLINE

8.1 Introduction	264	8.4 Combined Therapy	271
8.1.1 The Causative Agent: Leishmania	265	8.5 Other Drugs Used for Leishmaniasis	273
8.1.2 Life Cycle of Leishmania	266	8.5.1 Sitamaquine	273
8.1.3 Clinical Manifestations	267	8.5.2 8-Aminoquinolines	273
8.1.4 Pathology	267	8.5.3 2-Substituted Quinolines	274
8.2 Diagnosis	268	8.5.4 Buparvaquone and Its Derivatives	274
8.2.1 Parasitological Diagnosis	269	8.6 Macrophage-Targeted Drug Delivery Using Nanocarriers	275
8.2.2 Serological Diagnosis	269	8.6.1 Liposomes	275
8.2.3 Molecular Diagnosis	269	8.6.2 Nanoparticles	277
8.2.4 Antibody Detection Diagnostic Tests	270	8.6.3 Nanodisks	283
8.3 Currently Used Drugs for the Treatment of Leishmaniasis	270	8.6.4 Niosomes	283
8.3.1 Antimonial Agents	270	8.6.5 Emulsions	286
8.3.2 Pentamidine	270	8.6.6 Carbon Nanotubes	287
8.3.3 Amphotericin B	271	8.6.7 Transfersomes	287
8.3.4 Miltefosine	271	8.6.8 Other Drug Delivery Systems	288
8.3.5 Paromomycin	271		